Wells Fargo’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Wells Fargo’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8	Closed	-$810	–	7605
2024 Q1	$810	Buy	8 +1	+14%	+$63	﹤0.01%	6196
2023 Q4	$157	Buy	7 +1	+17%	+$17	﹤0.01%	6662
2023 Q3	$127	Hold	6	–	–	﹤0.01%	6698
2023 Q2	$161	Hold	6	–	–	﹤0.01%	6760
2023 Q1	$124	Hold	6	–	–	﹤0.01%	6892
2022 Q4	$119	Hold	6	–	–	﹤0.01%	6756
2022 Q3	$0	Buy	6 +1	+20%	+$29	﹤0.01%	7562
2022 Q2	$0	Sell	5 -594	-99%	-$26.4K	﹤0.01%	7678
2022 Q1	$48K	Sell	599 -268	-31%	-$33.1K	﹤0.01%	5683
2021 Q4	$176K	Sell	867 -915	-51%	-$228K	﹤0.01%	5340
2021 Q3	$576K	Buy	1,782 +1,457	+448%	+$425K	﹤0.01%	4587
2021 Q2	$84K	Buy	325 +137	+73%	+$41.7K	﹤0.01%	5358
2021 Q1	$72K	Buy	188 +113	+151%	+$45.6K	﹤0.01%	5638
2020 Q4	$31K	Buy	+75	New	+$23.6K	﹤0.01%	5739

Other funds holding VINC

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo's VINC Position: Q2 2024 in Review

Wells Fargo sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2024, closing a stake of 8 shares — an estimated $810 sold.

Wells Fargo first reported a position in VINC in Q4 2020 and held it in 14 quarters. The position peaked at $576K in Q3 2021. 27 funds tracked by Wall St. Rank hold VINC as of Q2 2024.

Wells Fargo reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Wells Fargo sold 8 Vincerx Pharma, Inc. Common Stock shares in Q2 2024, an estimated $810.
Wells Fargo first reported a position in Vincerx Pharma, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
Wells Fargo's Vincerx Pharma, Inc. Common Stock position peaked at $576K in Q3 2021.
27 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2024.

Based on Wells Fargo's 13F filing for Q2 2024, filed 13 Aug 2024.